Iran Unveils Locally Developed Microdrug to Treat Addiction
TEHRAN (Tasnim) – Iranian researchers have developed a microdrug to treat addiction, designed to reduce dependency on conventional detox medications and offer sustained effects.
The drug’s development process, which took around five years and included over 400 formulation trials, was showcased at the 15th International Nano and Micro Exhibition.
Unlike traditional addiction medications injected directly into the bloodstream, this microdrug utilizes polymer-based microspheres to encapsulate the drug, allowing it to be slowly released over 30 days.
In an interview with national television, a representative explained that "a month after injection, the addiction-related brain receptors are blocked, so even if a patient uses drugs or alcohol, they don't experience euphoria," which reduces their desire to use substances.
This innovative microdrug is not only aimed at treating addiction but has also been adapted for other treatments, such as extended pain relief for cancer patients.
While similar American drugs cost over $2,000, the Iranian version is priced under 3 million tomans, making it more accessible to local patients.
According to the Secretary of the Nanotechnology and Microtechnology Headquarters, sales of health-related nanoproducts have doubled compared to the previous year, with an economic impact exceeding direct sales due to reduced foreign currency outflow.
This year's Nano Exhibition features over 230 organizations, including around 60 companies focused especially on micro-technology products.